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compared with BEV  IFN and sunitinib. METHODS: A linear decision analytic
model was developed to assess the management costs of all-grade and grade 3/4 AEs
for BEV  LD IFN from the perspective of health care purchasers in Germany, France
and UK. Data sources included published cost literature and clinical trials, ofﬁ cial
price/tariff lists and country-speciﬁ c cost databases. RESULTS: The total side-effect 
management costs for BEV  LD IFN were €908, €1,381 and €703 in Germany, France
and UK, respectively. The use of BEV  LD IFN provides reduced management costs 
per patient of €616, €576 and €606, respectively, compared with BEV  IFN, and
€1,286, €3,746 and €1,647, respectively, compared with sunitinib. The main drivers 
for sunitinib costs were thrombocytopenia, neutropenia and lymphopenia compared 
with fatigue/asthenia, proteinuria and anaemia for BEV  LD IFN. CONCLUSIONS:
Costs of managing the side effects of sunitinib treatment are greater than those for 
BEV  IFN in Germany, France and UK [Mickisch, ASCO 2008]. The present analysis 
shows that combining BEV with LD IFN is associated with the lowest side effect 
management costs. The tolerability proﬁ les and associated management costs of agents
used in mRCC may therefore inﬂ uence selection of therapy.
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OBJECTIVES: The combination of BEV  interferon-alpha2a (IFN) prolongs progres-
sion-free survival compared with IFN  placebo [Escudier, Lancet 2007], providing 
comparable efﬁ cacy to sunitinib in patients with mRCC. Notably, the type and fre-
quency of side effects differ between the two regimens. When selecting treatment 
options, the management of side effects and associated costs are important factors to 
consider for physicians and health care payers. A previous report showed that grade 
3/4 adverse events (AEs) account for the majority of side-effect management costs 
[Mickisch, ASCO 2008]. We report here the results of an updated analysis of grade 
3/4 AE management costs for BEV  IFN and sunitinib. METHODS: A linear decision
analytic model was developed to compare the management costs of grade 3/4 AEs of 
BEV  IFN and sunitinib from the perspective of health care purchasers or hospital-
based care in Germany, France, the UK and Italy. Data sources included published 
cost literature and clinical trials, ofﬁ cial price/tariff lists and country-speciﬁ c cost 
databases. RESULTS: The grade 3/4 AE management costs for sunitinib were higher
than those for BEV  IFN in Germany (€1785 vs €1367), France (€2590 vs. €1618), 
UK (€1475 vs. €804) and Italy (€891 vs. €402). The main cost drivers were country
dependent, but in general were lymphopenia, leucopenia, neutropenia, thrombocyto-
penia and fatigue/asthenia for sunitinib; the main cost drivers for BEV  IFN were
proteinuria, fatigue/asthenia, bleeding, anaemia and gastrointestinal perforation. The
difference in management costs between the two regimens was mainly due to the 
higher incidence of haematological side effects with sunitinib compared with BEV 
IFN and their associated high management costs. CONCLUSIONS: The costs of 
managing AEs of sunitinib are greater than those for BEV  IFN in Germany, France,
UK and Italy. AE proﬁ les are therefore an important consideration when selecting
treatments for mRCC.
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OBJECTIVES: To assess the incidence rate and risk factors of severe infusion reactions 
(IRs), and to quantify the costs associated with their management in patients with 
colorectal cancer (CRC) treated with cetuximab. METHODS: Using administrative 
claims of a US national commercially insured population, the study evaluates patients
with CRC receiving cetuximab treatment from 2004 to 2006. An algorithm was 
developed to identify IRs using a combination of three indicators: outpatient diagnoses 
of signs/symptoms of IRs, outpatient treatment for IRs, and ER visits or hospitaliza-
tions for IRs. IRs were categorized as severe based on the occurrence of an ER visit/
hospitalization with an IR admitting diagnosis; or presence of both outpatient diag-
nosis of IR signs/symptoms and outpatient IR treatment. Total costs associated with
each cetuximab administration were calculated. A logistic regression was run to iden-
tify risk factors for IRs. A Generalized Linear Model regression controlling for demo-
graphic and clinical characteristics was conducted to quantify additional economic
impact of severe IRs. RESULTS: A total of 1,122 patients were identiﬁ ed with 12,367 
cetuximab administrations. The incidence of severe IRs was 8.4%. Approximately
38% of patients experiencing severe IRs required an ER visit or hospitalization. Mean 
adjusted costs were $6,339 for administrations resulting in a severe IR that required 
outpatient treatment only; $13,174 for administrations resulting in a severe IR that
required an ER visit or hospitalization; and $4,450 for administrations without an 
IR. Younger age was associated with a statistically higher likelihood of IRs. Living in
states with high pollen counts also had a trend of increased likelihood of severe IRs,
although it was not statistically signiﬁ cant. CONCLUSIONS: The rate of severe IRs
with cetuximab in clinical practice was found to be higher than that reported in the
product labeling and clinical trials. Total costs associated with managing severe IRs 
to payers were substantial.
CANCER – Cost Studies
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OBJECTIVES: Myeloid growth factors are used to treat and prevent chemotherapy-
induced neutropenia (CIN). Filgrastim and its long-acting version pegﬁ lgrastim are
granulocyte colony-stimulating factors (G-CSF), whereas sargramostim is a dual 
granulocyte-macrophage colony-stimulating factor (GM-CSF). This study analyzed 
the budget impact of substituting GM-CSF for G-CSF in the management of CIN from 
the perspective of a US health plan. METHODS: A spreadsheet model was developed
to compute annual and per-member-per-month (PMPM) costs associated with CSFs.
Inputs included cancer prevalence, the proportion of patients receiving chemotherapy 
and G/GM-CSFs, incidence and treatment cost of relevant adverse events (e.g., bone 
pain), and G/GM-CSF drug acquisition and administration costs. Incidence and cost 
of infection- and febrile neutropenia-related hospitalizations, based on recent analysis 
of medical insurance claims data, were also used. Cost savings (2006 USD) were
assessed for utilization share switches from G-CSF to GM-CSF. RESULTS: For a health 
plan with 1 million members, an estimated 976 patients received G/GM-CSF annually.
Modifying baseline utilization shares for pegﬁ lgrastim, ﬁ lgrastim, and sargramostim
of 70/30/0%, respectively, to alternative shares of 50/25/25% yielded almost $2 
million in annual cost savings, or $0.161 PMPM. Most of the cost savings were 
attributed to CSF acquisition and administration costs (81.8%), with lesser savings 
also observed for hospitalizations (14.6%) and adverse events (3.6%). Savings for
patients switching from pegﬁ lgrastim were greater than for patients switching from
ﬁ lgrastim. Results were sensitive to assumptions for drug cost and frequency of 
administration, but cost savings were observed for most scenarios. CONCLUSIONS:
This study suggests that health plans can realize substantial cost savings by substituting 
sargramostim for ﬁ lgrastim and pegﬁ lgrastim in CIN patients. With 25% of sar-
gramostim substitution, cost savings could reach more than 16 cents PMPM for a
typical US health plan.
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OBJECTIVES: Pemetrexed plus cisplatin (Cis/Pem) was recently approved in the US
as initial treatment for advanced nonsquamous NSCLC. We developed a budget 
impact model to estimate the effect on a US health plan budget of adopting Cis/Pem
for this new indication. METHODS: A deterministic Excel-based budget impact model
was developed from the perspective of a one million member US health plan over a 
one-year time horizon. A survey of nine US thoracic oncologists was used to quantify
the impact of introducing Cis/Pem as ﬁ rst-line therapy on the frequency of chemo-
therapy use and the choice of ﬁ rst- and second-line regimens. Results were calculated 
from SEER incidence rates and the anticipated changes in ﬁ rst- and second-line 
regimen utilization rates. The costs associated with each regimen were based on 
Medicare reimbursement rates and a claims database analysis. Model outputs included
health plan total cost, cost per patient per year, and per member per month (PMPM) 
costs. RESULTS: Following the adoption of Cis/Pem, total cost per patient per year 
for advanced NSCLC is estimated to decrease by $702 from $67,539 to $66,837.
Anticipating that the number of NSCLC patients receiving treatment over the course
of one year would increase slightly, a net additional cost to the health plan of $35,512 
is estimated. Overall a neutral PMPM cost ($0.00) is expected. Most sensitivity analy-
ses produce PMPM costs between $0.02 and $0.02. CONCLUSIONS: Introduction 
of Cis/Pem as ﬁ rst-line therapy is anticipated to reduce the use of less expensive doublet 
regimens including gemcitabine and paclitaxel; however, it is also anticipated to reduce 
the use of more expensive triplet regimens containing bevacizumab. When Cis/Pem is 
used as ﬁ rst-line therapy, alternative, and often less expensive, regimens are recom-
mended for use as second-line therapy. Overall, the adoption of Cis/Pem as ﬁ rst-line 
therapy for advanced nonsquamous NSCLC is anticipated to be budget neutral.
PCN21
BUDGET IMPACT ANALYSIS OF NON – SMALL CELL LUNG CARCINOMA
(NSCLC) TREATMENT WITH ERLOTINIB IN POLISH SETTING
Orlewska E1, Szczesna A2, Szkultecka-Debek M3
1Centrum Farmakoekonomiki, Warsaw, Poland, 2Regional Lung Diseases Hospital, Otwock, 
Poland, 3Roche Polska, Warsaw, Poland
OBJECTIVES: to assess the ﬁ nancial consequences of the introduction of erlotinib as
second/third line treatment of patients with IIIB/IV NSCLC in Poland. METHODS:
Two scenarios were compared: “baseline scenario” where 96% patients received 
